Evidence map›Paper›PMID 38589477›Full record

ArticleScientific reports2024

Plasmodium falciparum pfhrp2 and pfhrp3 gene deletions among patients enrolled at 100 health facilities throughout Tanzania: February to July 2021.

Eric Rogier, Nastassia Battle, Catherine Bakari, Misago D Seth, Douglas Nace, Camelia Herman, Achut Barakoti, Rashid A Madebe, Celine I Mandara, Beatus M Lyimo and 16 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
18.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Local variability inMalariaWorld journal · 2026
    Article
  8. Article
  9. Genetic metrics decodeFrontiers in genetics · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 8 institutions in 4 countries.

Eric RogierMalaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Nastassia BattleCDC Foundation, Atlanta, GA, USA.
Catherine BakariNational Institute for Medical Research, Dar Es Salaam, Tanzania.
Misago D SethNational Institute for Medical Research, Dar Es Salaam, Tanzania.
Douglas NaceMalaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Camelia HermanMalaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Achut BarakotiMalaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Rashid A MadebeNational Institute for Medical Research, Dar Es Salaam, Tanzania.
Celine I MandaraNational Institute for Medical Research, Dar Es Salaam, Tanzania.
Beatus M LyimoNational Institute for Medical Research, Dar Es Salaam, Tanzania.
David J GiesbrechtBrown University, Providence, RI, USA.
Zachary R Popkin-HallUniversity of North Carolina, Chapel Hill, NC, USA.
Filbert FrancisNational Institute for Medical Research, Tanga, Tanzania.
Daniel MbwamboNational Malaria Control Programme, Dodoma, Tanzania.
Issa GarimoNational Malaria Control Programme, Dodoma, Tanzania.
Sijenunu AaronNational Malaria Control Programme, Dodoma, Tanzania.
Abdallah LusasiNational Malaria Control Programme, Dodoma, Tanzania.
Fabrizio MolteniSwiss Tropical Public Health Institute, Dar Es Salaam, Tanzania.
Ritha NjauWorld Health Organization, Country Office, Dar Es Salaam, Tanzania.
Jane A CunninghamWorld Health Organization, Headquarters, Geneva, Switzerland.
Samwel LazaroNational Malaria Control Programme, Dodoma, Tanzania.
Ally MohamedNational Malaria Control Programme, Dodoma, Tanzania.
Jonathan J JulianoUniversity of North Carolina, Chapel Hill, NC, USA.
Jeffrey A BaileyBrown University, Providence, RI, USA.
Venkatachalam UdhayakumarMalaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Deus S IshengomaNational Institute for Medical Research, Dar Es Salaam, Tanzania. deusishe@yahoo.com.
African Malaria Network Trust · TZNational Institute for Medical Research · TZCenters for Disease Control and Prevention · USBrown University · USCDC Foundation · USUniversity of North Carolina at Chapel Hill · USMonash University · AUWorld Health Organization · CH

Funding

Bill and Melinda Gates Foundation Inv. No. 002202World Health Organization 001
6 · The paper itself

Abstract

Plasmodium falciparum with the histidine rich protein 2 gene (pfhrp2) deleted from its genome can escape diagnosis by HRP2-based rapid diagnostic tests (HRP2-RDTs). The World Health Organization (WHO) recommends switching to a non-HRP2 RDT for P. falciparum clinical case diagnosis when pfhrp2 deletion prevalence causes ≥ 5% of RDTs to return false negative results. Tanzania is a country of heterogenous P. falciparum transmission, with some regions approaching elimination and others at varying levels of control. In concordance with the current recommended WHO pfhrp2 deletion surveillance strategy, 100 health facilities encompassing 10 regions of Tanzania enrolled malaria-suspected patients between February and July 2021. Of 7863 persons of all ages enrolled and providing RDT result and blood sample, 3777 (48.0%) were positive by the national RDT testing for Plasmodium lactate dehydrogenase (pLDH) and/or HRP2. A second RDT testing specifically for the P. falciparum LDH (Pf-pLDH) antigen found 95 persons (2.5% of all RDT positives) were positive, though negative by the national RDT for HRP2, and were selected for pfhrp2 and pfhrp3 (pfhrp2/3) genotyping. Multiplex antigen detection by laboratory bead assay found 135/7847 (1.7%) of all blood samples positive for Plasmodium antigens but very low or no HRP2, and these were selected for genotyping as well. Of the samples selected for genotyping based on RDT or laboratory multiplex result, 158 were P. falciparum DNA positive, and 140 had sufficient DNA to be genotyped for pfhrp2/3. Most of these (125/140) were found to be pfhrp2+/pfhrp3+, with smaller numbers deleted for only pfhrp2 (n = 9) or only pfhrp3 (n = 6). No dual pfhrp2/3 deleted parasites were observed. This survey found that parasites with these gene deletions are rare in Tanzania, and estimated that 0.24% (95% confidence interval: 0.08% to 0.39%) of false-negative HRP2-RDTs for symptomatic persons were due to pfhrp2 deletions in this 2021 Tanzania survey. These data provide evidence for HRP2-based diagnostics as currently accurate for P. falciparum diagnosis in Tanzania.

Indexed as

Blood Group AntigensMalaria, FalciparumAntigens, ProtozoanDiagnostic Tests, RoutineDNAGene DeletionHealth FacilitiesHumansPlasmodium falciparumProtozoan ProteinsTanzaniaAntigens, ProtozoanBlood Group AntigensDNAProtozoan ProteinsGene deletionpfhrp2pfhrp3Plasmodium falciparumRDTTanzania

Identifiers

PMID38589477
PMCPMC11001933
OpenAlexW4394572182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.